|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Campo RA, Rowland JH, Irwin ML, Nathan PC,
Gritz ER and Kinney AY: Cancer prevention after cancer: changing
the paradigm - a report from the American Society of Preventive
Oncology. Cancer Epidemiol Biomarkers Prev. 20:2317–2324. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parkin DM: The global health burden of
infection-associated cancers in the year 2002. Int J Cancer.
118:3030–3044. 2006.PubMed/NCBI
|
|
5
|
El-Serag HB: Epidemiology of
hepatocellular carcinoma in USA. Hepatol Res. 37(Suppl 2): S88–S94.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mahata S, Bharti AC, Shukla S, Tyagi A,
Husain SA and Das BC: Berberine modulates AP-1 activity to suppress
HPV transcription and downstream signaling to induce growth arrest
and apoptosis in cervical cancer cells. Mol Cancer. 10:392011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luo Y, Hao Y, Shi TP, Deng WW and Li N:
Berberine inhibits cyclin D1 expression via suppressed binding of
AP-1 transcription factors to CCND1 AP-1 motif. Acta Pharmacol Sin.
29:628–633. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu HL, Hsu CY, Liu WH and Yung BY:
Berberine-induced apoptosis of human leukemia HL-60 cells is
associated with down-regulation of nucleophosmin/B23 and telomerase
activity. Int J Cancer. 81:923–929. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ghobrial IM, Witzig TE and Adjei AA:
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin.
55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luo Y, Hurwitz J and Massagué J:
Cell-cycle inhibition by independent CDK and PCNA binding domains
in p21Cip1. Nature. 375:159–161. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Dowbenko D and Lasky LA: AKT/PKB
phosphorylation of p21Cip/WAF1 enhances protein
stability of p21Cip/WAF1 and promotes cell survival. J
Biol Chem. 277:11352–11361. 2002.PubMed/NCBI
|
|
12
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Inohara N, Ding L, Chen S and Núñez G:
harakiri, a novel regulator of cell death, encodes a protein that
activates apoptosis and interacts selectively with
survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J.
16:1686–1694. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reed JC: Bcl-2 family proteins: regulators
of apoptosis and chemoresistance in hematologic malignancies. Semin
Hematol. 34:9–19. 1997.PubMed/NCBI
|
|
15
|
Earnshaw WC, Martins LM and Kaufmann SH:
Mammalian caspases: structure, activation, substrates, and
functions during apoptosis. Ann Rev Biochem. 68:383–424. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boulares AH, Yakovlev AG, Ivanova V,
Stoica BA, Wang G, Iyer S and Smulson M: Role of poly(ADP-ribose)
polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP
mutant increases rates of apoptosis in transfected cells. J Biol
Chem. 274:22932–22940. 1999. View Article : Google Scholar : PubMed/NCBI
|
